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Objectives: To report on the performance and cost of a surgeon-led renal cancer 
specialist multidisciplinary team meeting at a high-volume centre. 
Materials and methods: Retrospective analysis of 1500 consecutive cases discussed 
from 02/09/2015 onwards. Performance was assessed as the number of cases where 
a clinical recommendation was made. The cost per meeting, discussion, and patient 
were calculated using the mid-point of pay band attributable to the attendees (NHS 
pay scales 2015). 
Results: 1500 discussions occurred over 34 meetings (933 patients: 61.7% male; 
mean age 63.8). Above a quarter of discussions (n=399, 26.6%) were new referrals. 
Each patient’s case was discussed a mean of 1.6 times, the majority being discussed 
once (n=563, 60.3%). In 93.3% discussions a clinical recommendation was made. 
Only 100 discussions (6.7%) were deferred due to incomplete clinical information. 
11.1% (n=166) of cases were discharged. The average cost was: £141,901 per year, 
£2,729 per meeting, £62 per case discussed, and £99 per patient. 
Conclusion: One discussion was usually sufficient to decide management; deferral 
was uncommon; and, given the low discharge rate, referrals seemed appropriate. The 
cost per patient was modest and represented good value in providing a focused and 
shared clinical decision-making pathway for renal cancer patients. 
 
Level of evidence: 2C 
 
Keywords (MeSH) 




Multidisciplinary team (MDT) meetings are structured assemblies of individuals 
from different disciplines that occur at scheduled times with the aim of discussing the 
clinical management of a given patient1. These meetings (also known as tumour 
boards in other countries such as the USA) were established as a means to improve 
patient outcomes and develop a critical mass of knowledge by transferring the 
diagnostic and management decision from one individual to a group of experts from 
complementary disciplines. Based on this concept they were adopted as standard of 
care and, since the early 2000’s, it is mandated in the UK that all patients diagnosed 
with cancer are reviewed at MDT meetings1. MDT meetings must be regularly audited 
in the UK and have been shown to change patient management3, increase patient 
satisfaction4, and may contribute towards better clinical outcomes5. Furthermore, a 
recent discrete choice experiment involving patients, health professionals and the 
public found that access to a specialist MDT was a particular preference when 
selecting a specialist cancer surgery service provider6. 
There is evidence that centralisation of cancer surgical services is occurring on 
a global scale, including Europe and the USA. In the UK, particularly in London and 
Manchester, prostate, bladder, kidney and oesophageal cancer care have been 
rearranged into centralised high-volume centres where excellent levels of clinical and 
organisational expertise are expected to further improve treatment outcomes whilst 
also reducing costs6,7. 
At a time when the health services, including the National Health Service 
(NHS), are under unprecedented budget pressure, the ability to combine 
rationalisation of costs with high quality care and clinical benefit appears attractive. 
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The aim of our work is to use standardised metrics and report on the performance and 
cost efficiency of the surgeon-led specialist MDT (sMDT) meeting for the North Central 
and North East London renal cancer centre.
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Materials and methods 
 
The renal cancer specialist MDT meeting 
The renal cancer specialist MDT (sMDT) meeting is organised according to 
NHS recommendations. It is a weekly three-hour meeting hosted by The Royal Free 
Hospital (Royal Free London NHS Foundation Trust). All patients with confirmed or a 
high suspicion index of upper tract urological cancer from 13 referring hospital trusts 
across North Central and North East London are reviewed at this meeting. After the 
meeting, an outcome report is issued per case discussed and disseminated to 
referring clinicians. Discussion at the meeting precedes the clinic appointment with the 
patient and thus any informed discussion with the patient regarding the ensuing 
management options available usually occurs after MDT discussion. 
Participants of the meeting include both core and extended members from 
various medical fields (urology, oncology, radiology, interventional radiology, 
histopathology and nephrology). Core members are attendees that sit throughout the 
duration of the meeting and whose presence is necessary to establish quorum. These 
include the meeting chair (a urology consultant), consultant urologists, consultant 
radiologists, consultant oncologists, clinical nurse specialists, and sMDT meeting 
coordinator. Extended members are attendees that sit on the meeting either for a 
limited period of time to participate in the discussion of their referred cases or 
throughout the duration of the meeting but whose presence does not count towards 
establishing a minimum quorum necessary for decision making. Some extended 
members attend the meeting solely via videoconference. Additionally, each referring 
centre provides administrative support via a local MDT coordinator to organise the list 
of cases to be discussed and ensure all relevant clinical information (history, 
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examination, scan images, pathology reports and/or slides) is available at the time of 
the meeting. 
 
The NHS pay scale 
In the NHS, base annual salaries for all staff are predefined nationwide 
according to a scale8. This scale is further subdivided into bands and each band into 
spines. A range of bands is attributed to each type of job. Previous salary and level of 
expertise define the exact band each employee is allocated to, for example, a junior 
doctor is paid according to band 7, while consultants are paid band 8 to 9. The number 
of years working on the job defines the spine payment within each band (first year on 
the job corresponds to spine 1, second to spine 2, and so forth). 
 
Data collection and analysis 
We retrospectively reviewed 1500 consecutive case discussions at the renal 
cancer sMDT meeting starting from 02/09/2015, and conducted descriptive analysis 
of patient demographics, referring hospital, referring specialty, reason for discussion, 
average number of discussions per meeting, number of discussions per patient in the 
time period considered, number of cases deferred to subsequent meetings, and 
number of cases discharged back to the community care. Cases were categorised 
according to previous referral to the meeting into new referrals (no previous discussion 
prior to 02/09/2015) and previously discussed cases (previous discussion prior to 
02/09/2015). 
As previously described9, performance of the meeting was assessed by 
calculating the rate of cases where a clinical recommendation was made (for example, 
requirement of further imaging scans, treatment/management recommendation, 
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discharge, or post-treatment follow up scheme). Meeting decision implementation was 
not assessed. As MDT discussion usually precedes the clinic appointment with the 
patient, information on suitable management options made by the referring physician 
was in the main not available. Thus, it was not possible to assess if the sMDT ratified 
the referring physician’s management decision. 
To calculate the cost of running the meeting three factors were considered: the 
member attendance records of relevant meetings; the time spent at the meeting by 
core and extended members (3h for core members and the average time spent by 
each extended member at the last three meetings included in the analysis); and the 
time spent preparing or actioning on outcomes from the meeting. These are the 
costing metrics advised by the NHS to calculate MDT meeting cost10. MDT 
coordinators and lead core members (urology, oncology, radiology, pathology, 
nursing) provided information regarding the average amount of time per week devoted 
to preparing case discussions and actioning on meeting outcomes. All lead core 
members and 4 out of 13 MDT coordinators responded to the request for information. 
When an estimate of preparation time was not provided, this was estimated as a 
function of the number of cases per referring hospital discussed per meeting. Each 
member and MDT coordinator were classified according to banding using the NHS 
pay scales from 1 April 20158. The mid-spine value of each band was taken into 
consideration to calculate cost. When there were two mid-spine values, the lowest one 
was considered. London allowance was added to this value. 
The cost of each meeting was calculated as a function the NHS salary pay per 
hour of each coordinator and member per hour based on the three factors named 
above. The cost per case discussed, and per patient was calculated. The annual cost 
of the sMDT meeting was extrapolated. 
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The specialist renal cancer service at Royal Free Hospital was established in 
2014, after the UK mandate that all patients diagnosed with cancer must be discussed 
at a MDT, thus no control group of cases not discussed at the sMDT was available for 
outcome comparison. 
Reporting was done in accordance with the Revised Standards for Quality 











One thousand and five hundred case discussions took place over 34 meetings 
(02/09/2015 to 20/04/2016). All meetings had quorum. Overall, 1375 (91.7%) 
discussions were done in the context of disease localised to the kidney and 125 (8.3%) 
were held in the context of metastatic disease. These discussions represented a 
cohort of 933 patients with a mean age of 63.8 (interquartile range (IQR) 24; minimum 
14; maximum 96) and where 61.7% were male (n=576). Royal Free London NHS 
Foundation Trust referred most patients to the sMDT meeting (n=538, 57.7%), 
followed by University College London Hospitals Trust (n=108, 11.6%; Figure 1). 
Urology was the specialty that referred the majority of patients (n=720, 77.2%), 
followed by renal medicine (n=52, 5.6%), and oncology (n=45, 4.8%; Figure 2). 
On average, 44 case discussions took place per meeting, with an average of 4 
minutes spent per case discussion. Just above a quarter of discussions (n=399, 
26.6%) were new referrals. While most discussions were based on reviewing imaging 
scans, more than one in four (n=416, 27.7%) represented discussions to decide 
management based on biopsy or surgical pathology results.  
Each patient’s case was discussed a mean of 1.6 times: the majority of patients 
required one (n=563, 60.3%) or two case discussions (n=234, 25.1%) during the 
period studied. Eighty-nine (9.5%) patients required three discussions, thirty-four 
(3.6%) required 4 discussions, nine (1%) required 5, one (0.1%) required 6, and three 
(0.3%) required 7 discussions.  
Regarding meeting outcomes, in nearly two thirds of discussions (n=980, 
65.3%) an intervention recommendation was made (such as renal tumour biopsy, 
active surveillance, surgery, cryotherapy and/or systemic therapy). The post-operative 
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follow-up scheme was decided in 155 discussions (10.3%). Overall, 11.1% (n=166) of 
cases were discharged from care in the period considered.  Ninety-nine (6.6%) cases 
required further imaging prior to management recommendation. Only 100 discussions 
(6.7%) were deferred due to incomplete clinical data, such as unavailability of imaging 
scans or pathology reports or slides for review. Thus, 93.3% of sMDT discussions 
resulted in clinical recommendations, which was the chosen performance outcome 
measure for this study.  
The renal cancer sMDT meeting has 15 core members and 17 extended 
members (Table 1), with annual salaries varying from NHS Clinical Salary Band 4 to 
9 plus London Allowance. Four out of 13 MDT coordinators reported the time taken to 
prepare and action on outcomes from the meeting (range from 0.5 to 20h a week). For 
the remaining coordinators, time was estimated as a function of the number of cases 
per referring hospital discussed per meeting. Preparing and actioning on meeting 
outcomes involved 8.5h of consultant time (urology 2.5h, oncology 0.5h, 
histopathology 1.5h, radiology 4h) and 5h of clinical nurse specialist time. Based on 
the number of hours spent preparing for the meeting, the attendance record of 
meetings, and the amount of time each member spent at the meeting, the estimated 
average cost of the meeting was: £141,901 per year, £2,729 per meeting, £62 per 






Our analysis shows that our surgeon-lead renal cancer sMDT meeting is 
efficient and provides good value. In 1500 discussions over 34 meetings and spanning 
over 8 months, a clinical recommendation was made in 93.3% of discussions. 
Generally, one or two discussions were usually sufficient to make management 
recommendations, deferral of cases was uncommon, and, given the low discharge 
rate, referrals to the meeting seemed appropriate. Additionally, the meeting 
expenditure seemed reasonable: while the headline annual cost for the sMDT meeting 
seems high £141,901), the cost per patient is modest (£99) and is less than the cost 
of an outpatient clinic appointment within the NHS12. 
Cases that required only one sMDT discussion likely represent situations where 
patients who had been discussed at the meeting before 02/09/2015 needed review 
regarding follow up requirements (such as deciding a surveillance plan after surgery, 
or to review new images for patients on surveillance) or where recommendations were 
made that did not require repeat sMDT discussion (initiation of systemic treatment, 
watchful waiting, or best supportive care, or discharge). Several reasons could explain 
the need for three or more discussions in 14.6% of patients. The wide time span of the 
study (over 8 months) likely includes re-review of patients with clinical progression on 
surveillance schemes and allows coverage of the small renal mass clinical pathway 
adopted by the specialist centre; whereby patients very frequently start their 
management by having a renal tumour biopsy, the results of which are reviewed at 
the MDT (second discussion), that can be followed by active treatment, such as 
surgery, that generates a third sMDT discussion to ascertain the best post-operative 
follow up scheme based on surgical histology. The minority of patients discussed four 
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or more times likely represent highly complex situations, where multiple additional 
investigations where required and/or complications from treatment arose. 
The average time of 4 minutes per case discussion most likely reflects a wide 
time range that correlates positively with case complexity. Notwithstanding, this 
illustrates the fast pace of the meeting and the importance of pre-meeting case 
preparation. It may also illustrate that the clinical decision-making process for some of 
the cases was very straightforward, questioning the utility of discussing all cancer 
cases at the MDT. However, even for what seems the most straightforward scenario 
for a patient diagnosed with a renal mass, the management decision process can 
become more difficult than initially apparent. Consideration of lesion location and size 
may limit the technical feasibility of certain types of intervention such as renal tumour 
biopsy, partial nephrectomy, or ablative treatment. Likewise, present and previous 
medical history can dictate the choice of active surveillance over intervention, preclude 
the start of systemic treatment, or expose the need for further clinical investigations or 
treatments prior to decision of management of the renal lesion. One could advocate 
that given that 91.7% discussions were done in the context of disease localised to the 
kidney that the clinical decision making relies mostly on the surgeons and radiologists 
present at the meeting and that a separate meeting including pathologists and 
oncologists would suffice to discuss histology results (27.7% of discussions) and 
metastatic disease settings (8.3% of discussions). While the idea of streamlining 
MDTs is under discussion at present13, and is something we are considering at our 
centre, it is still unclear how this should be implemented. Often, a case is reclassified 
from “straightforward” to “complex” precisely because there was a MDT discussion 
where all key members were involved and contributed towards this decision. If a 
pathway outside MDT discussion were to be implemented for straightforward 
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situations, it is unclear who and how these would be triaged and what criteria should 
warrant MDT discussion. Likewise, given that MDT discussion is now considered the 
gold standard in the UK, it is not known if patients would accept to have their care 
diverge from that pathway. Further studies involving all stakeholders, including 
patients, are required to fully critically appraise the MDT discussion pathway and 
develop streamlining tools. 
There are two main limitations to our cost calculations: one is that an estimate 
of the gross salary per member was used to calculate cost (as opposed to using the 
actual salary of each member); the second is that only costs in salaries were taken 
into account and other costs, such as videoconferencing and other overheads, were 
not considered. These factors may have contributed to a lower meeting-associated 
expenditure when compared to previous UK reports14. Nonetheless, considering the 
similar member composition of sMDT meetings in the UK across different cancer types 
and the use of standardised NHS metrics for MDT cost calculation10, the overall salary 
associated cost calculated for this meeting may be used for reference indication for 
the cost of other specialist clinical service meetings. 
Given the current UK practice to discuss all patients at cancer MDT meetings, 
within the NHS it is not possible to formally compare the clinical efficacy and cost 
effectiveness of these meetings to the previous single clinician decision pathway using 
a contemporaneous comparative cohort. Historical cohort studies have many 
limitations. Additionally, as our specialist centre and its MDT were established after 
the UK mandate, the use of an historical cohort was not possible. On one hand, studies 
suggest that MDT meetings contribute to faster and more appropriate patient 
management3-5, particularly in unusual or rare situations15, are cost beneficial16, and 
lead to increased patient satisfation4. On the other hand, poor study design, 
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publication bias, and heterogeneity between study outcomes may prevent a factual 
assessment of the benefits (or lack thereof) of MDT discussions17. Additionally, some 
have pointed out that the need to discuss all diagnostic and treatment options for 
straightforward cases limits the resources available to discuss difficult situations18 and 
that the absence of the patient at the MDT decision-making threatens autonomy19. In 
fact, the UK MDT mandate was established before strong evidence of effectiveness 
was established, limiting accurate evaluation of its clinical benefit20. Our study is 
unable to address these controversies. However, we do show that, at a modest cost, 
the renal cancer sMDT meeting addresses the clinical management of a large volume 
of patients, has a lower deferral rate than previous reports14, and in more than 90% of 
cases defines focused and clinically valid management options that can be presented 
and discussed with patients. This data is encouraging and supports the continued use 
of a multidisciplinary decision-making platform for all renal cancer patients at a high-
volume expert centre. Streamlining MDT discussions is under consideration13 but 
further discussions are needed between all stakeholders to understand how this can 
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Figure and table legends 
 
Figure 1 – Referring trusts 
 
 




Core Members Extended Members 
MDT Coordinator Urology consultant x3 
MDT Chair (Urology consultant) Radiology consultant 
Oncology Lead (Oncology consultant) Nephrology consultant 
Histopathology Lead (Histopathology 
consultant) 
Histopathology consultant x3 
Imaging Lead (Radiology consultant) Interventional radiology consultant 
Urology consultant x3 Specialty registrar in Urology 
Oncology consultant x2 Specialty registrar in Oncology 
Radiology consultant Specialty registrar in Histopathology 
Interventional radiology consultant Clinical nurse specialist in urology 
Clinical nurse specialist in renal cancer Clinical nurse specialist in oncology 
Clinical nurse specialist in renal cancer Clinical research nurse 
Clinical nurse specialist in oncology Clinical trial practitioner 
 Renal Cancer navigator 
 
Table 1 – Renal cancer specialist MDT meeting members 
